Advicenne S.A. (FRA:3MM)

Market Cap	25.47M
Revenue (ttm)	5.90M
Net Income (ttm)	-6.21M
Shares Out	n/a
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	222
Open	1.706
Previous Close	1.734
Day's Range	1.706 - 1.752
52-Week Range	1.084 - 2.085
Beta	n/a
RSI	62.81
Earnings Date	Dec 19, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3MM

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.